



EMVision Medical Devices Ltd  
 ACN 620 388 230  
 Suite 4.01, 65 Epping Rd  
 Sydney NSW 2113  
 02 8667 5337  
 contact@emvision.com.au

# ASX Release

## STAGE 3 RECRUITMENT TARGET ACHIEVED AND VALIDATION TRIAL FDA ENGAGEMENT UNDERWAY


**EMVision Medical Devices Limited (ASX:EMV)** (“EMVision” or the “Company”) is pleased to advise that it has reached its recruitment target for Stage 3 of its multi-site clinical trial of 30 haemorrhagic stroke patients.

Rapid achievement of this target is attributed to the continued positive engagement and goodwill at the investigational sites as well as the introduction of several recruitment accelerating initiatives under Stage 3. In addition to haemorrhagic stroke patients, the Stage 3 cohort includes a large number of ischaemic stroke participants, providing valuable data to enhance EMVision’s AI algorithm’s “blood or not” and “ischaemia or not” neurodiagnostic capabilities. This dataset builds on the positive interim analysis previously reported from Stage 2 of the trial.<sup>1</sup> Following final participant recruitment, investigation sites will collate all relevant data, which will undergo verification by the study’s Contract Research Organisation (CRO), Avania, before final delivery to EMVision. Once all the data is received and verified, it will be analysed with Stage 3 results anticipated to be reported during H2 CY2024.

In addition, the Company’s FDA pre-submission package has been delivered and is under FDA review prior to a consultation meeting in the coming months. The FDA pre-submission is a critical confirmation of requirements for EMVision’s upcoming Validation clinical trial to support market entry. In parallel, activities to initiate the Validation clinical trial are well under way, including protocol finalisation, CRO appointment and engagement of luminary investigational sites.

**EMVision CEO**, Scott Kirkland, commented “This is another significant milestone for EMVision with Stage 3 building on an already extensive dataset for our breakthrough neurodiagnostic product. Once processed, we look forward to sharing results from this data, as well as outcomes from our upcoming meeting with the FDA and progress with our validation trial in pursuit of market entry. We would like to thank the dedicated clinical research teams at each of our recruiting sites, and all participants in the EMView study”.

### Roadmap to market entry and beyond



<sup>1</sup> ASX Announcement dated 27 May 2023 - Trial data confirms early ischaemia detection capabilities and ASX Announcement dated 27 March 2023 – Stage 2 Insights Confirm Diagnostic and Clinical Viability

This roadmap is indicative only and subject to change.

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Dejan Toracki  
 Head of Investor Relations  
 +61 409 340 641  
[dtoracki@emvision.com.au](mailto:dtoracki@emvision.com.au)

Sling & Stone  
 Media and Communications  
[emvision@slingstone.com](mailto:emvision@slingstone.com)  
 02 8073 5390

Scott Kirkland  
 CEO and Managing Director  
 +61 2 8667 5337  
[skirkland@emvision.com.au](mailto:skirkland@emvision.com.au)

### Clinical Investigations Roadmap

The sites have been activated progressively, commencing with Liverpool Hospital. All sites that have been selected are major stroke centres that treat significant volumes of stroke patients each year.

TITLE	'EMVIEW' EMVision Gen 1 Brain Scanner Study on Acute Stroke Participants	
DEVICE DESCRIPTION	The EMVision Brain Scanner is a device system which obtains images of human brain using electromagnetic (microwave) techniques.	
STUDY SITES	<b>Site 1</b> - Liverpool Hospital <b>Site 2</b> - Royal Melbourne Hospital <b>Site 3</b> - Princess Alexandra Hospital Additional site to be added and activated as required	
PARTICIPANTS	Presenting to Emergency Department with suspected stroke	
PATIENT COHORT	Pre-validation Phase <b>Stage 1:</b> 30 Healthy participants <b>Stage 2:</b> Up to 150 Acute stroke/stroke mimic participants <b>Stage 3:</b> Up to 30 bleeds	Validation Phase Endpoint and sample size will be confirmed during the pre-validation phase
ENDPOINTS	<ul style="list-style-type: none"> <li>Hardware verification</li> <li>Safety</li> <li>Stroke mimic and acute stroke data to enhance AI algorithms</li> </ul>	<ul style="list-style-type: none"> <li>Efficacy (sensitivity/specificity)</li> <li>Safety</li> </ul>
DURATION & REPORTING	Anticipated to be 12+ months. The Company expects to provide updates to the market as it reaches relevant milestones throughout the clinical testing	
INCLUSION CRITERIA	Adults ≥ 18 years of age. Presenting to hospital with acute neurological deficit suspect to be stroke and within 24 hours of symptom onset. The use of the EMV Brain Scanner will not delay the treatment of the participant. CT brain imaging following clinical evaluation in Emergency Department per standard of care. Ability to provide informed consent. Participants will provide written informed consent. Where this is not possible, consent from a legal authorized representative will be obtained. Head size deemed suitable for scanning with the EMVision Brain Scanner.	
EXCLUSION CRITERIA	Has received treatment for current (suspected) stroke event prior to initial CT scan AND EMVision Brain Scanner scan. Pregnant or breastfeeding. Contraindication to neuroimaging, such as a contrast allergy or other condition that prohibits CT, MRI and/or angiography. Presence of any implanted electro-stimulating devices in the head and neck. Presence of any large metallic craniofacial implants, such as bone fixation plates, mesh etc. (Note that small metallic objects, such as aneurysm coils etc., are acceptable) Presence of an intracranial pressure monitor or any other similar sensor that may compromise the placement of the investigational device Inability to wear the investigational device (skin lesions on scalp, previous intracranial surgeries etc.). Unable to lie still for the duration of the scan. Any other condition or symptoms preventing the participant from entering the study, according to the investigator's judgment	
SCANNING PROCESS FOR A TYPICAL STROKE PATIENT		

## **About EMVision Medical Devices**

EMVision Medical Devices Limited (ASX:EMV) is an innovative Australian medical device company developing a novel approach to looking inside the human body. Our product pipeline includes portable, non-invasive, affordable and safe neuroimaging devices.

Our vision is to help transform and improve the timely diagnosis and treatment of stroke and other time sensitive medical emergencies, at the point-of-care.

EMVision has offices in Sydney and Brisbane [www.emvisionmedical.com](http://www.emvisionmedical.com)

## **Forward-looking Statements**

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

## **Inherent risks of Investment in Medical Device development Companies**

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore investment in Companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.